Pooled safety analyses of 2 phase 3 trials revealed similar tolerability of the IL-17A inhibitor secukinumab in children and adolescents with moderate-to-severe plaque psoriasis.
Digital health apps offer those affected by depression the possibility of supporting psychotherapy. Dr. sc. hm. Gwendolyn Mayer explains what these apps are about, who they are suitable for and how effective they are.
When a person is at the end of their life, it means change. At Heidelberg University Hospital, a team of therapists works with the concept of Dignity Therapy according to Chochinov and expands it to include the aspect of couple relationships.
The number of mental illnesses worldwide is growing - and with it the need for good therapies. What is the benefit of treating depression and anxiety with virtual reality? Researchers from New Zealand have evaluated studies.
What does the Covid-19 pandemic do to people psychologically? This questions was addressed in a lecture at the University Hospital Jena, Germany.
Most rheumatism drugs can be used safely in SARS-CoV-2 infections. Some even seem to protect against severe cases, but individual drugs were associated with a complicated disease path.
Recent advances in immuno-oncology could open up new treatment options for cardiovascular diseases in the future. A team from Heidelberg (Germany) and Stanford (USA) has found decisive steps in this direction.
Dr. Bianco shares his thoughts on the condition of hospitalised patients, in particular the elderly, and stresses the importance of humanising care in the medical profession.
An international team succeeds on the path to better understand the manifestations of this hereditary disease.
The Roman legions are considered a model of military efficiency. Military medicine was structured, including Greek influences and rituals, to provide care to these exceptional combatants.
An annotated guide to the Guidelines for Home Treatment of SARS-CoV-2 infections - by Dr Carla Bruschelli
Progression of disability in patients with POMS can be predicted by relapse frequency, greater number of relapses with incomplete recovery, amongst others.
PPMS who were originally randomised to ocrelizumab had a lower risk of disability progression than original placebo receivers after 8-years of follow-up.
Ibudilast was associated with reduced retinal atrophy compared with placebo in patients with primary progressive MS (PPMS). This was not the case for SPMS.
Ublituximab was superior to teriflunomide in relapsing MS patients. Annualised relapse rates and MRI parameters demonstrated this.
MS patients treated with ocrelizumab, rituximab, or fingolimod showed a reduced immune response after SARS-CoV-2 mRNA vaccination.
[11C]flumazenil (FMZ) positron emission tomography (PET) demonstrated higher GABA-receptor binding for cognitively preserved (CP) MS patients.
Evobrutinib significantly reduced MRI activity and patient numbers with qualified MS relapses regardless of baseline blood neurofilament light chain levels.
A newly developed dynamic scoring system can be used to support the decision whether or not to switch at an early stage from first- to second-line therapy.
The number of cortical lesions at MS diagnosis accurately discriminates between the presence of absence of cognitive impairment after 20 years.